Preferred Label : rucaparib;
CISMeF synonym : PF-01367338; AG 014699;
MeSH hyponym : AG014699; AG-014699;
Is substance : O;
UNII : 8237F3U7EH;
Origin ID : C531549;
UMLS CUI : C3661315;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also (suggested by CISMeF)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3506437/fr/rubraca-rucaparib-cancer-de-l-ovaire
2024
false
false
false
France
fallopian tube neoplasms
peritoneal neoplasms
treatment outcome
insurance, health, reimbursement
administration, oral
rucaparib
evaluation of the transparency committee
rucaparib
ovarian neoplasms
Rucaparib Camsylate
---
https://ansm.sante.fr/informations-de-securite/rucaparib-rubraca-recommandation-temporaire-de-ne-pas-initier-de-traitement-en-troisieme-ligne-therapeutique-compte-tenu-de-la-diminution-de-la-survie-globale-par-rapport-au-traitement-de-reference-analyse-intermediaire-de-letude-co-338-043-ariel4
2022
false
false
false
France
French
pharmacovigilance note
survival
rucaparib
Carcinoma, Ovarian Epithelial
fallopian tube neoplasms
peritoneal neoplasms
risk assessment
Poly(ADP-ribose) Polymerase Inhibitors
rucaparib
guidelines
---
https://www.cancer.fr/catalogue-des-publications/inhibiteurs-de-parp-olaparib-niraparib-rucaparib-talazoparib
2022
false
false
false
France
practice guideline
talazoparib
olaparib
Poly(ADP-ribose) Polymerase Inhibitors
talazoparib
rucaparib
olaparib
niraparib
niraparib
olaparib
rucaparib
---
https://ansm.sante.fr/informations-de-securite/cancer-epithelial-de-lovaire-des-trompes-et-du-peritoine-primitif-rucaparib-rubraca-ne-doit-plus-etre-utilise-en-3-ligne
2022
false
false
false
France
French
pharmacovigilance note
guidelines for drug use
survival analysis
rucaparib
rucaparib
treatment outcome
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
Maintenance Therapy
---
https://www.has-sante.fr/jcms/p_3112630/fr/rubraca
2020
false
false
false
France
rucaparib
rucaparib
administration, oral
treatment outcome
insurance, health, reimbursement
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
adult
Poly(ADP-ribose) Polymerase Inhibitors
evaluation of the transparency committee
indoles
---
https://www.ema.europa.eu/medicines/human/EPAR/Rubraca
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
rucaparib
drug approval
europe
treatment outcome
rucaparib
orphan drug production
ovarian neoplasms
fallopian tube neoplasms
peritoneal neoplasms
adult
mutation
fallopian tube neoplasms
ovarian neoplasms
peritoneal neoplasms
administration, oral
tablets
Poly(ADP-ribose) Polymerase Inhibitors
Poly(ADP-ribose) Polymerase Inhibitors
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
genes, BRCA1
genes, BRCA2
drug evaluation, preclinical
rucaparib
indoles
indoles
indoles
---